Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia.
+ 3 more risks
Excellent balance sheet and overvalued.
Share Price & News
How has Actinogen Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3AC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 3AC underperformed the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: 3AC underperformed the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Actinogen Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Actinogen Medical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 3AC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 3AC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 3AC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 3AC is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3AC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3AC is good value based on its PB Ratio (2x) compared to the DE Biotechs industry average (3.3x).
How is Actinogen Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3AC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 3AC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 3AC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 3AC's revenue is expected to decline over the next 3 years (-39.9% per year).
High Growth Revenue: 3AC's revenue is forecast to decline over the next 3 years (-39.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 3AC's Return on Equity is forecast to be high in 3 years time
How has Actinogen Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3AC is currently unprofitable.
Growing Profit Margin: 3AC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 3AC is unprofitable, and losses have increased over the past 5 years at a rate of -20.7% per year.
Accelerating Growth: Unable to compare 3AC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3AC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 3AC has a negative Return on Equity (-56.27%), as it is currently unprofitable.
How is Actinogen Medical's financial position?
Financial Position Analysis
Short Term Liabilities: 3AC's short term assets (A$9.2M) exceed its short term liabilities (A$809.3K).
Long Term Liabilities: 3AC's short term assets (A$9.2M) exceed its long term liabilities (A$329.9K).
Debt to Equity History and Analysis
Debt Level: 3AC is debt free.
Reducing Debt: 3AC has not had any debt for past 5 years.
Inventory Level: 3AC has a low level of unsold assets or inventory.
Debt Coverage by Assets: 3AC's debt is not covered by short term assets (assets are -1.6650092449885E+17x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3AC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 3AC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -32.9% each year
What is Actinogen Medical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3AC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 3AC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3AC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3AC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3AC's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. John William Ketelbey, also known as Bill, MBBCH, FFPM, MBA, GAICD, has been the Chief Executive Officer and Managing Director at Actinogen Medical Limited since December 18, 2014. Dr. Ketelbey is res ...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD275.04K) is below average for companies of similar size in the German market ($USD428.66K).
Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.
|MD, CEO & Director||5.33yrs||AU$457.69k||0.085% A$12.8k|
|Non-Executive Director||2.33yrs||AU$71.66k||0.018% A$2.7k|
|Non-Executive Chairman||3.08yrs||AU$160.02k||0.12% A$17.7k|
|Member of Xanamem Clinical Advisory Board||5.08yrs||no data||no data|
|Member of Xanamem Clinical Advisory Board||5.08yrs||no data||no data|
|Non-Executive Director||1yr||AU$18.53k||0.045% A$6.7k|
|Chairman of Xanamem Clinical Advisory Board||5.08yrs||no data||no data|
Experienced Board: 3AC's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.8%.
Actinogen Medical Limited's company bio, employee growth, exchange listings and data sources
- Name: Actinogen Medical Limited
- Ticker: 3AC
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$26.790m
- Listing Market Cap: AU$14.922m
- Shares outstanding: 1.12b
- Website: https://www.actinogen.com.au
- Actinogen Medical Limited
- 109 Pitt Street
- Suite 901
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ACW||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Oct 2007|
|3AC||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 2007|
|ACW||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Oct 2007|
|ATGG.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Oct 2007|
Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia. It is developing Xanamem, a therapy for Alzheimer’s disease; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. The company is also developing XanaHES, a Phase I, single blinded, central reader blinded, placebo-controlled, dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited is based in Sydney, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/06 23:28|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.